PMID-16822960 – CJC-1295 Normalizes Growth in GHRH Knockout Mice
Alba M, Fintini D, Bowers CY, Salvatori R. Effects of long-acting growth hormone-releasing hormone analogue (CJC-1295) in growth hormone-deficient adults. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
Quick Reference
| Property | Value |
|---|---|
| PMID | 16822960 |
| DOI | 10.1152/ajpendo.00201.2006 |
| Year | 2006 |
| Journal | American Journal of Physiology – Endocrinology and Metabolism |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | GHRH knockout mice (lit/lit model) |
| Peptide(s) Studied | CJC-1295 NO DAC |
Key Findings
- Once-daily CJC-1295 administration fully normalized growth in GHRH knockout (lit/lit) mice
- Body weight and body composition were restored to wild-type levels
- Pituitary GH content was normalized, confirming CJC-1295 can replace endogenous GHRH signaling
- Serum IGF-1 levels were elevated to wild-type range
- The results demonstrate that CJC-1295 provides complete functional GHRH replacement
- Single daily dosing was sufficient for full effect, supporting practical clinical dosing regimens
Study Design
GHRH knockout mice (lit/lit), which have severely impaired GH secretion due to absence of GHRH signaling, received once-daily CJC-1295 injections over a chronic treatment period. Wild-type littermates served as reference controls. Growth parameters (body weight, body length), body composition (lean mass, fat mass), pituitary GH content, and serum IGF-1 were measured at study endpoints.
Limitations
- Genetic GHRH knockout model represents complete absence of GHRH — clinically, most GH-deficient patients have partial rather than complete GHRH deficiency
- Mouse growth physiology differs from adult human physiology in important ways
- No assessment of potential adverse effects of chronic supraphysiological GHRH-receptor stimulation
- Single dose level used — no dose optimization
- No comparison with exogenous GH replacement as a positive control
Clinical Relevance
This study provides strong proof-of-concept that CJC-1295 can fully replace GHRH signaling. For clinicians, this means CJC-1295 (with or without DAC) has the potential to address GH deficiency at the hypothalamic level — stimulating the patient's own pituitary to produce GH rather than replacing it with exogenous GH. This "top-down" approach preserves physiological feedback mechanisms and pulsatility. The efficacy of once-daily dosing supports the practical clinical protocols currently used with CJC-1295 NO DAC (often dosed at bedtime to amplify the natural nocturnal GH pulse).
Related
#research #animal-in-vivo #CJC-1295 #evidence-level-V